Filing Flows › Krystal Biotech (KRYS) › Operating margin
Krystal Biotech (KRYS) operating margin by quarter
Krystal Biotech's operating margin was 55.9% in Q3 2026 (third quarter 2026), +6.9 pts from Q2 2026. Over the last 7 quarters it ranged from 41.0% (Q2 2025) to 55.9% (Q3 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 55.9% | +6.9 pts | +13.6 pts |
| Q2 2026 | 49.0% | +2.9 pts | +8.0 pts |
| Q1 2026 | 46.1% | +4.8 pts | +5.0 pts |
| Q4 2025 | 41.3% | -1.0 pts | — |
| Q3 2025 | 42.3% | +1.3 pts | — |
| Q2 2025 | 41.0% | -0.1 pts | — |
| Q1 2025 | 41.1% | — | — |
Q3 2026 at a glance
Krystal Biotech, Q3 2026: revenue $127M (+30% year over year), operating margin 55.9%, net earnings $63.1M, operating cash flow $91.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Krystal Biotech's operating margin?
Krystal Biotech's operating margin was 55.9% in Q3 2026 (third quarter 2026), +6.9 pts from Q2 2026.
How has Krystal Biotech's operating margin changed?
Over the last 7 quarters it ranged from 41.0% (Q2 2025) to 55.9% (Q3 2026).